Published in J Immunol on January 15, 2007
Th17 cells in human disease. Immunol Rev (2008) 4.27
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol (2008) 2.39
Essentials of Th17 cell commitment and plasticity. Blood (2013) 1.95
Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol (2009) 1.91
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest (2009) 1.87
The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A (2008) 1.85
IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol (2009) 1.77
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood (2009) 1.67
The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol (2008) 1.51
IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood (2007) 1.50
Suppression by TFR cells leads to durable and selective inhibition of B cell effector function. Nat Immunol (2016) 1.44
Intraepithelial lymphocytes in celiac disease immunopathology. Semin Immunopathol (2012) 1.41
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis (2011) 1.41
The anti-inflammatory mechanisms of Hsp70. Front Immunol (2012) 1.31
IL-21 limits peripheral lymphocyte numbers through T cell homeostatic mechanisms. PLoS One (2008) 1.28
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol (2009) 1.18
Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. Immunology (2011) 1.17
Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol (2011) 1.16
IL-15: a central regulator of celiac disease immunopathology. Immunol Rev (2014) 1.14
Regulatory T cells overturned: the effectors fight back. Immunology (2009) 1.13
Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev (2013) 1.05
Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med (2011) 1.03
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells. J Immunol (2014) 1.00
Interleukin-21 triggers effector cell responses in the gut. World J Gastroenterol (2010) 0.98
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci (2015) 0.98
Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther (2008) 0.97
T cell-derived interleukin (IL)-21 promotes brain injury following stroke in mice. J Exp Med (2014) 0.93
IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response. Diabetes (2011) 0.92
The yin and yang of regulatory T cells and inflammation in RA. Nat Rev Rheumatol (2010) 0.92
A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther (2010) 0.90
Th17 cells and transplant acceptance. Transplantation (2010) 0.90
Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proc Natl Acad Sci U S A (2011) 0.90
Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes. J Immunother (2009) 0.89
Cytotoxic-T-lymphocyte-associated antigen 4 blockade abrogates protection by regulatory T cells in a mouse model of microbially induced innate immune-driven colitis. Infect Immun (2008) 0.89
A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res (2012) 0.89
Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance. J Allergy Clin Immunol (2013) 0.88
Reduced IL-2 expression in NOD mice leads to a temporal increase in CD62Llo FoxP3+ CD4+ T cells with limited suppressor activity. Eur J Immunol (2011) 0.88
Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy (2011) 0.88
IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells. J Immunol (2014) 0.87
Forkhead transcription factors in chronic inflammation. Int J Biochem Cell Biol (2009) 0.87
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. BMC Neurol (2016) 0.86
IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4 T cell- and B cell-intrinsic mechanisms. J Immunol (2012) 0.86
CD4 T cell differentiation in type 1 diabetes. Clin Exp Immunol (2015) 0.86
Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol (2012) 0.85
Involvement of interleukin-15 and interleukin-21, two gamma-chain-related cytokines, in celiac disease. World J Gastroenterol (2009) 0.85
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression. Front Immunol (2016) 0.83
Interleukin-21 suppresses the differentiation and functions of T helper 2 cells. Immunology (2015) 0.83
Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-β-induced regulatory T-cell development. Immunology (2013) 0.83
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer (2014) 0.83
Multiple vaccinations: friend or foe. Cancer J (2011) 0.83
IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res (2015) 0.83
Th17 plasticity and its changes associated with inflammatory bowel disease. World J Gastroenterol (2015) 0.82
The PTPN22 1858T allele but not variants in the proximal promoter region of IL-21 gene is associated with the susceptibility to type 1 diabetes and the presence of autoantibodies in a Brazilian cohort. Clin Exp Immunol (2013) 0.81
The role of interleukin-21 in HIV infection. Cytokine Growth Factor Rev (2012) 0.81
Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81
The p38 mitogen-activated protein kinase cascade modulates T helper type 17 differentiation and functionality in multiple sclerosis. Immunology (2015) 0.80
Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype. J Immunol Res (2015) 0.80
IL-21 receptor signalling partially mediates Th2-mediated allergic airway responses. Clin Exp Allergy (2014) 0.79
Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunol Immunother (2012) 0.78
Decreased somatic hypermutation induces an impaired peripheral B cell tolerance checkpoint. J Clin Invest (2016) 0.78
Changes in natural Foxp3(+)Treg but not mucosally-imprinted CD62L(neg)CD38(+)Foxp3(+)Treg in the circulation of celiac disease patients. PLoS One (2013) 0.78
Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes. J Autoimmun (2016) 0.78
Interleukin-21 administration to aged mice rejuvenates their peripheral T-cell pool by triggering de novo thymopoiesis. Aging Cell (2016) 0.77
Endogenous IL-21 regulates pathogenic mucosal CD4 T-cell responses during enhanced RSV disease in mice. Mucosal Immunol (2012) 0.77
IL-21 Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma. Clin Transl Immunology (2013) 0.76
Mechanisms of autoimmunity in the non-obese diabetic mouse: effector/regulatory cell equilibrium during peak inflammation. Immunology (2016) 0.76
CREM Alpha Enhances IL-21 Production in T Cells In Vivo and In Vitro. Front Immunol (2016) 0.75
IL-21/IL-21R signaling suppresses intestinal inflammation induced by DSS through regulation of Th responses in lamina propria in mice. Sci Rep (2016) 0.75
Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients. J Immunother (2016) 0.75
Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response. Onco Targets Ther (2015) 0.75
Coeliac disease: a unique model for investigating broken tolerance in autoimmunity. Clin Transl Immunology (2016) 0.75
Role of IL-21 in HTLV-1 infections with emphasis on HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Med Microbiol Immunol (2017) 0.75
The circadian gene Arntl2 on distal mouse chromosome 6 controls thymocyte apoptosis. Mamm Genome (2016) 0.75
Interleukin 21 inhibits cancer-mediated FOXP3 induction in naïve human CD4 T cells. Cancer Immunol Immunother (2017) 0.75
The effect of IL-21 and CD4(+) CD25(++) T cells on cytokine production of CD4(+) responder T cells in patients with myasthenia gravis. Clin Exp Immunol (2017) 0.75
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest (2004) 5.14
Immunity, inflammation, and allergy in the gut. Science (2005) 4.82
Citrobacter rodentium of mice and man. Cell Microbiol (2005) 4.76
Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol (2005) 3.00
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest (2005) 2.41
Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med (2011) 2.41
Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology (2008) 2.38
Central role for B lymphocytes and CD4+ T cells in immunity to infection by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun (2003) 2.22
In vivo bioluminescence imaging of the murine pathogen Citrobacter rodentium. Infect Immun (2006) 2.07
The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity (2012) 1.97
The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol (2002) 1.91
Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology (2008) 1.88
Regulation of homeostasis and inflammation in the intestine. Gastroenterology (2011) 1.82
Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-gamma. J Immunol (2002) 1.80
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
IL-23/IL-17 axis in IBD. Inflamm Bowel Dis (2010) 1.71
Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol (2010) 1.66
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 1.55
A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem (2003) 1.54
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol (2008) 1.53
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's disease. J Crohns Colitis (2011) 1.52
IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol (2007) 1.49
Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest Endosc (2006) 1.46
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med (2009) 1.45
Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets (2008) 1.43
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease. J Crohns Colitis (2012) 1.40
Characterization of IL-17A-producing cells in celiac disease mucosa. J Immunol (2010) 1.40
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology (2006) 1.38
Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol (2008) 1.35
Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol (2008) 1.33
Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol (2004) 1.32
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med (2011) 1.27
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood (2008) 1.25
Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J Immunol (2009) 1.22
Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology (2007) 1.19
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology (2009) 1.19
Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm Bowel Dis (2009) 1.18
Inhibition of NF-κB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J Immunol (2010) 1.17
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology (2006) 1.17
A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts. Gastroenterology (2005) 1.16
Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol (2011) 1.16
Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis (2008) 1.15
New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.15
Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflamm Bowel Dis (2007) 1.15
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology (2005) 1.14
Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology (2007) 1.14